icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 485 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC)
 
 
  Reported by Jules Levin
EASL 2013 April 26 Amsterdam
 
H Fontaine1, C Hezode2, C Dorival3, D Larrey4, F Zoulim5,V de Ledinghen6, V Canva7, L Alric8, M Bourliere9, S Pol1, T Poynard10, G Riachi11, PH Bernard12, JJ Raabe13, J Gournay14, S Metivier15, JM Pawlotsky16, D Samuel17, Y Barthe3, F Carrat3, JP Bronowicki18, for the ANRS CO 20 CUPIC study group.
 
1.Hopital Cochin, Paris, 2. Hopital Henri Mondor, Creteil, 3. UMR-S 707, Paris, 4. Hopital Saint-Eloi, Montpellier, 5. INSERM U871, Lyon, France, 6.Hopital Haut Lêveque, Bordeaux, France 7. Hopital Clude Hurriez, Lille, France, 8. Medecine Interne, Hopital Purpan, Toulouse, 9. Fondation Saint-Joseph, Marseille, France, 10. Hepatologie, Hopital de la Pitie-Salpetriere, Paris, France 11. Hopital Charles Nicolle, Rouen, France, 12. Hoptal Saint-Andre, Bordeaux, France, 13. Hopital Bon Secours, Metz, France, 14. Hopital Universitaire de Nantes, Nantes, France 15. Hepatogastroenterologie, Hopital Purpan, Toulouse, France, 16. Hopital Henri Mondor, Creteil, France 17. Hopital Paul Brousse, Villejuif, France 17. Hopital de Brabois, Nancy, France

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

EASL12.gif